Introduction
For decades, the question of how psychedelics produce their extraordinary effects remained one of pharmacology's great puzzles. Today, we know that classical psychedelics -- LSD, psilocybin, DMT, and mescaline -- exert their primary effects by activating the serotonin 5-HT2A receptor, a G protein-coupled receptor found predominantly in cortical neurons. This single molecular interaction triggers a cascade of events that alters perception, dissolves ego boundaries, and may rewire neural circuits. The story of the 5-HT2A receptor is the story of psychedelic science itself.
The Receptor and Its Distribution
The serotonin 2A receptor (5-HT2A) is one of 14 serotonin receptor subtypes. It is a seven-transmembrane domain G protein-coupled receptor expressed most densely in layer V pyramidal neurons of the cerebral cortex, particularly in the prefrontal cortex, as well as in the claustrum and other association cortices. This distribution pattern is significant: these are the brain's highest-level integrative regions, responsible for combining sensory information, generating predictions, and maintaining the coherent model of reality that constitutes ordinary consciousness.
The receptor was first linked to psychedelic action through the work of Glennon, Titeler, and Lyon in the 1980s, who showed that the binding affinity of various psychedelics at 5-HT2 receptors correlated with their potency in producing behavioral effects in animals. The definitive human evidence came from Franz Vollenweider's group at the University of Zurich in the late 1990s, who demonstrated that ketanserin, a selective 5-HT2A antagonist, completely blocked the subjective effects of psilocybin in healthy volunteers.
Signaling Pathways: Not All Activation Is Equal
A major advance in the field has been the recognition that 5-HT2A receptor activation can engage multiple downstream signaling pathways, and that the psychedelic experience depends on specific pathway engagement. The receptor couples to several G proteins and other effectors:
Gq signaling activates phospholipase C, leading to increased intracellular calcium and protein kinase C activation. This is the canonical signaling pathway for 5-HT2A receptors.Gi signaling was identified in a 2025 study published in Nature by a team at the University of North Carolina. This non-canonical pathway appears essential for hallucinogenic effects. The researchers demonstrated that psychedelics that activate Gi signaling through 5-HT2A produce subjective effects, while compounds that activate only the Gq pathway do not.Beta-arrestin recruitment represents a third pathway. Research has shown that 5-HT2A-Gq efficacy, but not beta-arrestin2 recruitment, predicts psychedelic potential as measured by the head-twitch response in mice.
This concept of "biased agonism" -- where different ligands at the same receptor can selectively activate different signaling cascades -- has become central to psychedelic drug design. It suggests the possibility of developing compounds that retain therapeutic effects while minimizing unwanted aspects of the psychedelic experience.